Company:Chugai Pharmaceutical Co.

From HandWiki
Revision as of 20:40, 9 February 2024 by Rtexter1 (talk | contribs) (add)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Japanese pharmaceutical company
Chugai Pharmaceutical Co., Ltd.
Native name
中外製薬株式会社
Chūgai Seiyaku kabushiki gaisha
TypePublic KK
IndustryPharmaceutical Industry, Business import, production and development of drugs for medical sales
FoundedMarch 8, 1943
HeadquartersNihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo
On the registration Headquarter: Tokyo Kita (Tokyo)
Key people
Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO
Revenue72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated
(December 2007)
ParentHoffmann-La Roche (61.62%)
Websitewww.chugai-pharm.co.jp (in Japanese)

Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014.[1] The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.

History

Timeline

This is a timeline of important events of Chugai Pharmaceutical.[2]

  • 1925: Juzo Ueno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines
  • 1927: Start of the first own production
  • 1930: Salobrocanon, an analgesic (pain reliever) and antipyretic is launched
  • 1937: Calcium bromide production begins
  • 1943: Name changed to Chugai Pharmaceutical Co., Ltd. based in Tokyo
  • 1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga
  • 1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt
  • 1946: Construction of the plant in Kamagiishi
  • 1951: Guronsan®, a drug to detoxify and restore liver function is launched
  • 1952: Varsan®, a perspiration insecticide is launched
  • 1955: Chugai became a public company
  • 1956: The stock is listed on the Tokyo Stock Exchange
  • 1957: Construction of the Ukima plant
  • 1960: Establishment of a research center (Takada Research Laboratory, Tokyo)
  • 1967: Foundation of Fukushima Kasai Co Ltd.
  • 1961 – Developed patents for synthesis of vitamin A
  • 1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.
  • 1971: Construction of the factory in Fujieda
  • 1975: Picibanil®, a cancer drug is launched
  • 1982: Opening of a branch in New York
  • 1986: Opening of a branch in London
  • 1989: Acquisition of Gen-Probe Incorporated (USA)
  • 1990: Epogin® launched
  • 1995 – Released acute promyelocytic sphere of leukemia drug treatment Vesanoid®
  • 1996 – Released anti-viral chemotherapeutic agent Hivid® (HIV reverse transcriptase inhibitor)
  • 1997 – Released HIV protease inhibitor Invirase®
  • 1999 – Released immunosuppressive agent Cellcept®
  • 2000 – Released antiemetic drug Kytril®, developed to combating the side effects of chemotherapy
  • 2001 – Produced anti-influenza virus Tamiflu (Roche)
  • 2002: Start of the alliance with Roche
  • 2003: Xeloda®, a cancer drug is launched
  • 2005: Actemra® launched
  • 2007: Copegus®, an antiviral, Avastin®, a cancer drug, and Tarceva®, a cancer drug launched
  • 2011 – Produced Actemra®, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
  • 2014: Launch of Kadcyla®, a cancer drug, Chugai Pharma China Co Ltd. founded
  • 2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.[3]
  • 2016: Cooperation between Osaka University and Chugai
  • 2018: Tecentriq®, a cancer drug is launched
  • 2020 – FDA approved satralizumab (Enspryng) for treatment of the orphan disease neuromyelitis optica[4]

See also

  • Biotech and pharmaceutical companies in the New York metropolitan area

References

  1. ↑ Cortez, Michelle Fay; Matsuyama, Kanoko (25 August 2014). "Roche Said to Have Decided Against Bid for Rest of Chugai". Bloomberg. https://www.bloomberg.com/news/2014-08-24/roche-said-to-have-decided-against-bid-for-rest-of-chugai.html. 
  2. ↑ "History of Chugai Pharmaceutical". December 23, 2015. https://www.chugai-pharm.co.jp/english/profile/history/index.html. 
  3. ↑ Staff (2 March 2015). "Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership". Genetic Engineering & Biotechnology News. http://www.genengnews.com/gen-news-highlights/chugai-to-co-develop-athersys-cell-therapy-in-japan-in-up-to-205m-partnership/81250978/. Retrieved 2016-06-11. 
  4. ↑ "FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord". 17 August 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-disease-affecting-optic-nerves-spinal-cord. 

External links




Retrieved from "https://handwiki.org/wiki/index.php?title=Company:Chugai_Pharmaceutical_Co.&oldid=3484022"